GSK drug halves attacks in hard-to-treat asthma
LONDON (Reuters) – An experimental drug for treating severe asthma from GlaxoSmithKline nearly halved the number of attacks suffered by patients with a hard-to-treat form of the disease in a clinical study, boosting hopes for its commercial success.
August 16th, 2012
Posted in
Drug